Post by CPTx

Just wrapped up an energizing few days at #BioEquityEurope! 🙌   Our CEO Hendrik Dietz presented CPTx’s vision for non-viral, DNA-based in vivo CAR T cell engineering. The conversations that followed were incredibly exciting and encouraging.   In vivo CAR T has real momentum right now, and it’s clear the industry is paying close attention to differentiated approaches that can truly scale cell therapy beyond the limits of ex vivo manufacturing.   BioEquity Europe offered the right environment to make meaningful connections with great people: investors, industry leaders, and innovators alike. A big thank you to the organizers Eric, Brian, Stephen & the whole team at BioCentury Inc. for putting together such a well-organized and impactful event. See you next year at BioEquity Europe in Copenhagen!   Reach out if you’d like to learn more about our approach to in vivo CAR T cell engineering using immune-quiet single-stranded DNA + LNPs!   #InVivoCART #CellTherapy #ssDNA #Biotech #BioEquityEurope #CPTx